BioCentury
ARTICLE | Company News

Genzyme, Ablynx partner in MS

May 19, 2015 12:29 AM UTC

Ablynx N.V. (Euronext:ABLX) and the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) partnered to develop Nanobodies against an undisclosed multiple sclerosis target. Ablynx's Nanobodies are therapeutic proteins based on single-domain antibody fragments.

Neither company would discuss the target, but Ablynx said the program would align with Genzyme's early stage research involving neuroprotection and CNS repair, intended to slow disease progression. ...